The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver（2022）
Abstract
In recent years, the development of ustekinumab and vedolizumab has further improved the treatment of inflammatory bowel disease (IBD), offering additional therapeutic options to achieve induction and maintenance of remission in both ulcerative colitis (UC) and Crohn's disease (CD). However, data about the impact on extra-intestinal manifestations (EIMs) of IBD are limited [1]. In this issue, Margolin et al. [2] have reported the effect of ustekinumab and vedolizumab in EIMs of IBD.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined